Everything below concerns Research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
====== Palliative medicine ====== To train in the add-on specialty of palliative medicine a physician must first be a specialist in one of the pediatric class specialties, one of the independent class specialties (excluding occupational and environmental medicine, clinical pharmacology, clinical genetics, forensic medicine, and social medicine), one of the internal medicine class specialties, one of the surgical class specialties, one of the neurological class specialties (excluding clinical neurophysiology) or one of the psychiatric class specialties.
The receptors for enkephalin are the δ-opioid receptor (DOR) and μ-opioid receptor (MOR). Opioid receptors are a group of G-protein-coupled receptors, with other opioids as ligands as well. The other endogenous opioids are dynorphins (that bind to κ-opioid receptor), endorphins (MOR), endomorphins, and nociceptin-orphanin FQ. The opioid receptors are ~40% identical to somatostatin receptors (SSTRs).
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. As acrylamide derivatives are often used in drug discovery to make covalent inhibitors which will bind irreversibly to its target, acrylfentanyl is claimed to be naloxone resistant. However, acute intoxications with acrylfentanyl on mice treated by naloxone (2 mg/kg) have shown that acrylfentanyl could be displaced from the opioid receptor. Acrylfentanyl has been linked to 20 deaths in Sweden as well as two deaths in Denmark in summer 2016.
In November 2020, Hetero signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture more than 100 million doses of Sputnik V, the world’s first registered COVID-19 vaccine. Hetero continued its response to COVID-19 with the launch of Movfor (molnupiravir) in late 2021 and Nirmacom (a generic version of nirmatrelvir-ritonavir) in 2022. In December 2022, Nirmacom became the first generic adaptation of the COVID treatment to receive WHO prequalification, allowing Hetero to distribute it to 95 LMICs under a voluntary license administered through the Medicines Patent Pool. 2023- Present In 2023, Hetero celebrated 30 years of its journey from a small-time API producer to a global pharmaceutical manufacturing powerhouse. In 2024, Hetero entered a partnership with Gilead Sciences to expand availability of Lenacapavir, a long acting injectable HIV treatment, across 120 high-incidence countries in order to support the global HIV response. In 2025, Hetero opened a new commercial office in Warsaw, Poland, marking the company’s formal entry into the Eastern European pharmaceutical markets. In 2026, Hetero launched generic versions of semaglutide - the active ingredient in medicines for type 2 diabetes and obesity management- in emerging markets under the names Truglyx, Rolmodl, and Moto G.
He soon determined that random X chromosome inactivation causes tissue mosaicism in female mammals, in that each somatic cell expresses one (but not both) of the alleles of X-linked genes with which it is endowed. This he accomplished by showing that two populations of erythrocytes exist in the blood of African American women who are heterozygous for G6PD deficiency. Mary F. Lyon independently hypothesized that variegated coat colors in mice might arise from random X chromosome inactivation. This, too, flowed from Ohno's observations. Beutler's seminal work on G6PD deficiency led him to further explore hemolytic anemias caused by various enzyme deficiencies. The systematic methodology that he developed became the standard approach to study of patients with these disorders. Beutler made major contributions to the understanding of Tay–Sachs disease. He purified the enzyme that is aberrant in this disease and demonstrated its multimeric structure. His group cloned the gene responsible for Gaucher disease and developed treatments for this disease, as well as diagnostic tests. Beutler also developed a screening test for galactosemia, which is used to this day to detect the disease in neonates, and prevent its severe consequences. Beutler was the first to attempt pharmacologic intervention in sickle cell disease by increasing methemoglobin levels, carboxyhemoglobin levels, and fetal hemoglobin levels. The latter approach depended on administration of estrogen, progesterone and human chorionic gonadotropin.
Sources: en.wikipedia.org
Hegseth had announced on 10 October the formation of a new counternarcotics joint task force, to operate in Latin America, the Western hemisphere, and the area of the United States Southern Command (USSOUTHCOM), to be headed by the II Marine Expeditionary Force, intended "to crush the cartels, stop the poison and keep America safe". On 13 November 2025, Hegseth announced the unveiling of Operation Southern Spear, led by Joint Task Force Southern Spear and using a fleet with robotics and autonomous systems to target Latin American drug trafficking, with operations to begin later in November. A US official told a reporter in November that Hegseth's 13 November unveiling was "a formal operation naming for what the Joint Task Force Southern Spear ... and Southcom have already been doing in theater".
{\displaystyle h=0.425{{\left[{\frac {k_{vf}^{3}{{\rho }_{vf}}g\left({{\rho }_{L}}-{{\rho }_{v}}\right)\left({{h}_{fg}}+0.4{{c}_{pv}}\left({{T}_{s}}-{{T}_{sat}}\right)\right)}{{{\mu }_{vf}}\left({{T}_{s}}-{{T}_{sat}}\right){\sqrt {\sigma /g\left({{\rho }_{L}}-{{\rho }_{v}}\right)}}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
Alice in Chains has sold over 30 million certified records in the United States, released two number-one albums, had 23 top 40 singles, and has received eleven Grammy Award nominations. The band was ranked number 34 on VH1's 100 Greatest Artists of Hard Rock. Alice in Chains was named 15th greatest live band by Hit Parader, with Staley placing as 27th-greatest heavy metal vocalist of all time. The band's second album, Dirt, was named 5th-best album in the last two decades by Close-Up magazine in 2008. In October 2008, Guitar World ranked Cantrell's solo in "Man in the Box" at No. 77 on their list of "100 Greatest Guitar Solos". In August 2009, Alice in Chains won the Kerrang! Icon Award. In November 2011, Jar of Flies was ranked number four on Guitar World magazine's top ten list of guitar albums of 1994. It was also featured in Guitar World magazine's "Superunknown: 50 Iconic Albums That Defined 1994" list, and in May 2014, the EP was placed at number five on Loudwire's "10 Best Hard Rock Albums of 1994" list. In June 2017, Metal Injection ranked Alice in Chains at number 1 on their list of "10 Heaviest Grunge Bands". Ozzy Osbourne ranked Facelift among his list of "10 Favorite Metal Albums".
==== Kidnapping and extortion ransoms ==== Colombia is a country in which many people are or have been kidnapped. Kidnapping, as one of the manifestations that underlie armed conflict, carries both direct and indirect costs. The former consists mainly of the payment of ransoms and the expenses assumed by the State to control and prevent kidnapping. Indirect costs include, "[...] the loss of human capital for the duration of the detention and for the death of the kidnapped during his captivity". There are two types of kidnapping:
=== Lipedema stages === Lipedema is classified by stage: Stage 1: Normal skin surface with enlarged hypodermis (lipedema fat). Stage 2: Uneven skin with indentations in fat and larger hypodermal masses (lipomas). Stage 3: Bulky extrusions of skin and fat cause large deformations, especially on the thighs and around the knees. These large extrusions of tissue drastically inhibit mobility.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.